Poster Efficacy and Safety of Loncastuximab tesirine and Rituximab (Lonca-R) Followed by DA-R-EPOCH in Previously Untreated High-Risk DLBCL: Preliminary Results from UCDCC#303, a UCHMC Phase II Trial
Poster Consolidation with Loncastuximab Tesirine for Large B-cell Lymphoma Patients in Partial Response After CART: Planned Interim Futility Analysis of a Phase II Trial
Poster HuB14-VA-PL2202, a novel antibody-drug conjugate targeting ASCT2, a novel ADC target over-expressed in both solid and hematological cancers
Poster A phase II trial of loncastuximab tesirine in patients with previously treated Waldenström macroglobulinemia
Poster Loncastuximab Tesirine in Combination with Venetoclax Is Safe and Shows Efficacy in Patients with Relapsed/Refractory Non Hodgkin Lymphoma
Poster Limited Duration Loncastuximab Tesirine Induces a High Rate of Complete Responses in Patients with Relapsed/Refractory Marginal Zone Lymphoma – Report of First Planned Interim Futility Analysis of a Multicenter Phase II Study
Poster A Phase 2 Study of Loncastuximab Tesirine Plus Mosunetuzumab In Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Poster Quantitative Systems Pharmacology Modeling of Loncastuximab Tesirine Combined With Mosunetuzumab and Glofitamab Helps Guide Dosing for Patients With DLBCL
Poster Quantitative Systems Pharmacology Modeling of Mipasetamab Uzopterine Integrates Knowledge and Defines Dosing Strategy for Patients With Sarcoma